N-[(3-phenylphenyl)carbamoyl]quinoxaline-6-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(3-phenylphenyl)carbamoyl]quinoxaline-6-carboxamide
• 化学式: C₂₂H₁₆N₄O₂
• 分子量: 368.4
• InChiKey: CEHDPNIVRONKKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Antagonists of MCP-1 function and methods of use thereof
  申请人：——

  公开号：US20030105085A1

  公开（公告）日：2003-06-05

  Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

  对 MCP-1 功能具有拮抗作用的化合物，可用于预防或治疗慢性或急性炎症性或自身免疫性疾病，特别是与淋巴细胞或单核细胞异常积聚有关的疾病，如关节炎、哮喘、动脉粥样硬化、糖尿病肾病、炎症性肠病、克罗恩病、多发性硬化、肾炎、胰腺炎、肺纤维化、牛皮癣、再狭窄和移植排斥反应；包括这些化合物的药物组合物；以及利用这些化合物和组合物预防或治疗这些疾病。
• ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF
  申请人：TELIK, INC.

  公开号：EP1363897A2

  公开（公告）日：2003-11-26
• US6809113B2
  申请人：——

  公开号：US6809113B2

  公开（公告）日：2004-10-26
• US7297696B2
  申请人：——

  公开号：US7297696B2

  公开（公告）日：2007-11-20
• [EN] ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF<br/>[FR] ANTAGONISTES DE LA FONCTION MCP-1 ET PROCEDE D'UTILISATION DE CEUX-CI
  申请人：TELIK INC

  公开号：WO2002070509A2

  公开（公告）日：2002-09-12

  The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.